Theocharis Panaretakis, M.D.
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Education & Training
Degree-Granting Education
| 2003 | Karolinska Institutet, Solnavagen, USA, PHD, Experimental Oncology |
| 1997 | University of Sussex, Falmer, GBR, BS, Biochemistry |
Experience & Service
Academic Appointments
Associate Professor, Department of Genitourinary Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present
Visiting Associate Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2019
Principal investigator, Department of Department of Oncology-Pathology, Karolinska Institutet, Stockholm, 2010 - 2016
Assistant Professor, Department of Department of Oncology-Pathology, Karolinska Institutet, Stockholm, 2009 - Present
Associate Professor, Karolinska Institutet, Stockholm, 2009 - Present
Selected Publications
Peer-Reviewed Articles
- Koinis F, Corn P, Parikh N, Song J, Vardaki I, Mourkioti I, Lin SH, Logothetis C, Panaretakis T, Gallick G. Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer. Cancers (Basel) 12(1), 2020. e-Pub 2020. PMID: 31963871.
Grant & Contract Support
| Title: | Response Evaluation of Finite Systemic Therapy with Advanced Androgen Signaling Inhibition and Radiation Therapy for Oligorecurrent Prostate Cancer (RESTART) |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-Investigator |